Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES

Inclusion Criteria: 1. Age\>18 2. Diabetes mellitus 3. Documented CAD: stable or unstable angina, Non-ST segment MI, silent ischemia or positive functional study 4. PCI considered appropriate and feasible 5. Culprit de novo lesion in a native coronary artery with significant stenosis (\>50% by visual estimate) eligible for stent implantation (no limitation on the number of treated lesions, vessel and lesion length); 6. Patient provides written informed consent 7. Patient agrees to all required follow-up procedures and visits. 8. Target lesion suitable for PCI with DES diameter between 2.5 and 4.0 mm. Exclusion Criteria: 1. The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, ticlopidine, sirolimus, everolimus, and/or contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled); 2. Any contraindication to the implant of the Abluminus DES+ 3. Subject is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or does not consistently use effective methods of contraception;; 4. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions; 5. Previous coronary intervention on target vessel in the 3-months prior to enrollment; 6. Non-cardiac co-morbid conditions with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment); 7. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period; 8. Previously documented left ventricular ejection fraction (LVEF) \<30%; 9. Evident cardiogenic shock before randomization; 10. Patients with left main stem stenosis (\>50% by visual estimate); 11. In-stent restenosis; 12. ST-segment elevation MI; 13. Chronic total occlusion. 14. Culprit lesion to a Saphenous Vein graft